Haemonetics Corp.

As of October 17, 2025, Haemonetics Corp. is undervalued with a P/E ratio of 22 and an attractive valuation grade, despite a year-to-date return of -35.63%, indicating potential for recovery compared to the S&P 500's gain of 13.30%.

As of October 17, 2025, Haemonetics Corp. is considered undervalued with a P/E ratio of 22 compared to the peer average of 16.35, strong operational efficiency indicators like an ROE of 18.58%, and despite a year-to-date return of -35.63%, it presents a compelling investment opportunity.

As of August 15, 2025, Haemonetics Corp. is in a bearish trend, indicated by negative signals from MACD, Bollinger Bands, moving averages, and underperformance against the S&P 500, with year-to-date returns of -34.49% compared to the index's 12.22%.

As of August 25, 2025, Haemonetics Corp. is rated very attractive due to its undervaluation with a P/E ratio of 22 compared to the peer average of 16.35, a favorable ROE of 18.58%, and a lower EV/EBITDA ratio of 13.04, despite a year-to-date stock performance of -34.49% against the S&P 500's 12.22% return.

As of May 8, 2025, Haemonetics Corp. is considered an attractive investment with a fair valuation, showing strong metrics like a P/E ratio of 22 and a ROE of 18.58%, despite a 15.40% decline in stock performance over the past year.

As of May 6, 2025, the market trend is mildly bearish, influenced by daily moving averages and mixed signals from MACD, Bollinger Bands, KST, and OBV indicators.

As of March 2022, Haemonetics Corp.'s management team includes CEO Christopher Simon and several independent directors, including Richard Meelia (Chairman), Robert Abernathy, Catherine Burzik, Michael Coyle, Charles Dockendorff, and Mark Kroll.

Haemonetics Corporation is a healthcare company specializing in blood processing, handling, and analysis products. As of March 2025, it reported net sales of $331 million and a net profit of $58 million, with a market cap of approximately $3.32 billion.

As of Jun 18, Haemonetics Corp. has a market capitalization of 3,315.03 million, with net sales of 1,360.82 million and a net profit of 167.67 million over the latest four quarters. Shareholder's funds are 820.84 million, and total assets are 2,450.95 million.